Lixte Biotechnology provides update on recent corporate activities

LIXTE Biotechnology (LIXT) provided an update on its recent activities. Summary of Recent Corporate Activities: Completion of two financings: a private placement with accredited investors, raising aggregate gross proceeds to the Company of approximately $5M, and a registered direct offering with accredited investors, raising aggregate gross proceeds to the Company of approximately $1.5M. Proceeds will be used for general corporate purposes and working capital and allowed the Company to regain compliance for continued listing on the Nasdaq Capital Market. Management and Board changes: Geordan Pursglove was appointed Chairman and CEO in June 2025, succeeding Bas van der Baan, who became President and Chief Scientific Officer. Jason Sawyer and Michael Holloway, MD, joined LIXTE’s Board as independent directors in July 2025, succeeding Stephen Forman, MD, and Yun Yen, MD, who were appointed to serve as members of a newly established Scientific Advisory Committee. Other committee members include Bas van der Baan and Board member Rene Bernards, PhD. Validation of LB-100: The medical journal Nature has published findings that validate LIXTE’s ongoing clinical trials with LB-100. A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of patients treated with immune checkpoint blockade therapy. The study showed that patients having tumors with inactivating mutations in PPP2R1A – the major scaffold subunit of protein phosphatase 2A – had significantly better overall survival, compared with patients who did not have this mutation in their tumors. New Pre-Clinical trial: LIXTE has initiated a new pre-clinical study in collaboration with Netherlands Cancer Institute to test whether “initiated” cells that carry mutations found in cancer cells can be eliminated by treatment with LB-100. The study represents a new opportunity in cancer prevention.